{"id":12360,"date":"2008-06-24T12:35:00","date_gmt":"2008-06-24T10:35:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/rassegna-stampa-farmaceutica-dal-20-al-23-giugno-di-aboutpharma\/"},"modified":"2008-06-24T12:35:00","modified_gmt":"2008-06-24T10:35:00","slug":"rassegna-stampa-farmaceutica-dal-20-al-23-giugno-di-aboutpharma","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/rassegna-stampa-farmaceutica-dal-20-al-23-giugno-di-aboutpharma\/","title":{"rendered":"PHARMACEUTICAL PRESS REVIEW from 20 to 23 June of AboutPharma"},"content":{"rendered":"<p class=\"MsoNormal\"><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">Press Review from<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\"> <strong><span style=\"font-weight: bold\">20<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">\/06\/08<\/span><\/font><\/strong><\/strong><\/span><\/strong>&nbsp;<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">to the<\/span><\/font><\/strong><\/strong>&nbsp;<strong><span style=\"font-weight: bold\">23<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">\/06\/08<\/span><\/font><\/strong><\/strong><\/span><\/strong>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#000080\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: navy; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/strong><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">&quot;Inquiry into drugs, AIFA leaders suspended&quot;<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Il Sole 24 Ore: page 14, Il Messaggero: page 12, Corriere della Sera: page 19, Libero: page 16, la Repubblica: page 17, Il Mattino: page 12 \u2013 22 June 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">The General Manager of AIFA Nello Martini was suspended, as a precaution for 2 months, from his functions and with him also Caterina Gualano, manager for marketing authorizations. The accusation is of &#039;culpable disaster with conscious negligence&#039;, inherent in the investigation into the delayed updating of the leaflets of some drugs. Martini will ask for an international expert opinion and will present an appeal to the Lazio Regional Administrative Court, where the investigation has been transferred.<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=17020\" target=\"_blank\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/notizia.asp?id=17020<\/a><\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">&quot;Newron auctions ralfinamide jewel&quot;<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Stock Exchange &amp; Finance: page 9 \u2013 21 June 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">Newron Pharmaceuticals may sell rights to experimental painkiller ralfinamide. This measure would give a boost to the biotech company&#039;s shares which have recorded a decrease of 36.8% since the beginning of 2008. Newron is also evaluating the hypothesis of external growth: CEO Luca Benatti believes that &#039;with an acquisition you enter the market faster. The ideal target would be a company similar to Newron&#039;.<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=17021\" target=\"_blank\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/notizia.asp?id=17021<\/a><\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span","protected":false},"excerpt":{"rendered":"<p>Rassegna Stampa dal 20\/06\/08&nbsp;al&nbsp;23\/06\/08&nbsp; &nbsp; &quot;Inchiesta sui farmaci, sospesi i vertici di AIFA&quot; (Il Sole 24 Ore: pag. 14, Il Messaggero: pag. 12, Corriere della Sera: pag. 19, Libero: pag. 16, la Repubblica: pag. 17, Il Mattino: pag. 12 &#8211; 22 giugno 2008) Il Direttore Generale di AIFA Nello Martini &egrave; stato sospeso, cautelativamente per &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12360"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12360\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}